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Introduction
Antibodies are important tools in biomedical research. They 
allow the identification of new genes, the purification of proteins, 
and the study of protein properties such as structure, function 
and localization.1,2 Most of these applications use polyclonal anti-
bodies, which are produced in response to multiple epitopes of 
the same target protein (antigen). Polyclonal antibodies are usu-
ally raised against a specific protein by immunising an animal 
with the target protein in its purified form.1
The most effective way of obtaining the high quantities of 
antigenic protein required for efficient immunisation is by het-
erologous expression in a host cell. The bacteria Escherichia coli 
The production of recombinant antigens in Escherichia coli and specific polyclonal antibodies for diagnosis and therapy 
is still a challenge for world-wide researchers. several different strategies have been explored to improve both antigen 
and antibody production, all of them depending on a successful expression and immunogenicity of the antigen. Gene 
fusion technology attempted to address these challenges: fusion partners have been applied to optimise recombinant 
antigen production in E. coli, and to increase protein immunogenicity. Taking a 12-kDa surface adhesion antigen from 
Cryptosporidium parvum (cp12) by example, the novel h fusion partner was presented in this work as an attractive option 
for the development of recombinant immunogens and its adjuvant-free immunisation. The h tag (of only 1 kDa) efficiently 
triggered a cp12-specific immune response, and it also improved the immunisation procedure without requiring co-
administration of adjuvants. Moreover, polyclonal antibodies raised against the hcp12 fusion antigen detected native 
antigen structures displayed on the surface of C. parvum oocysts. The h tag proved to be an advanced strategy and 
promising technology for the diagnosis and therapy of C. parvum infections in animals and humans, allowing a rapid and 
simple recombinant production of the cp12 antigen.
A novel adjuvant-free H fusion system for the 
production of recombinant immunogens in 
Escherichia coli
Its application to a 12 kDa antigen from Cryptosporidium 
parvum
sofia J costa1,2, pedro silva2,3, andré almeida4,5,*, antónia conceição3, Lucília Domingues1, and antónio castro2
1Institute for Biotechnology and Bioengineering; centre of Biological engineering; Universidade do Minho, campus de Gualtar; Braga, portugal; 2Instituto Nacional de saúde 
Dr Ricardo Jorge; porto, portugal; 3escola superior agrária de coimbra; coimbra, portugal; 4Instituto de ciências e Tecnologias agrárias e agroalimentares da Universidade do 
porto; porto portugal; 5hitag Biotechnology, Lda.; Biocant – parque Tecnológico de cantanhede; cantanhede, portugal
Keywords: novel fusion partner, immunogens, free-adjuvant immunisation, antibody production, Cryptosporidium, CP12
Abbreviations: BB-SpG, region BB of Streptococcal protein G; CP12, 12-kDa surface adhesion antigen from Cryptosporidium 
parvum; CTB, Cholera toxin B; ELISA, enzyme-linked immunosorbent assay; Fh8, 8-kDa excreted-excreted antigen from Fasciola 
hepatica; GST, gluthathione S-transferase; H, 1-kDa fusion partner that corresponds to the 11-residue N-terminal sequence of the 
Fh8 antigen; MBP, maltose binding protein; O.D., optical density; SpA, Streptococcal protein A; SSNAP, sparingly soluble non-
antigenic protein; TgOWP, oocyst wall protein from Toxoplasma gondii; Trx, thioredoxin
is one of the most widely used organisms for this purpose, as 
it is easy to manipulate, has a fast growth rate and is relatively 
cheap to use.3-8 However, it also has its limitations; the recom-
binant protein it produces is not always correctly folded or suf-
ficiently soluble for use in immunisation. The development of 
alternative strategies for protein production that overcome these 
drawbacks is therefore highly desirable.5,9,10 One such strategy is 
the gene fusion technology, whereby the gene coding for the pro-
tein of interest is fused to a polypeptide chain, known as a fusion 
partner.
Fusion partners can simplify protein purification, improve 
protein production yield, reduce susceptibility to proteolysis and 
increase protein solubility.6,11-14 They have also been reported to 
increase protein immunogenicity.1,15-18
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adjuvants are associated with non-specific immune responses 
and can cause several side effects and lesions at the injection 
site.2,18,21,22 Therefore, the use of recombinant fusion partners 
for protein and antibody production has evidently much room 
for improvement.
This work presents the novel H fusion partner for the recombi-
nant production in E. coli and subsequent adjuvant-free immuni-
sation of the 12-kDa recombinant protein, CP12 (GenBank 
ID: XM625821.1), belonging to the parasite Cryptosporidium 
parvum (C. parvum). The H partner consists of an 11 residues 
sequence from the N-terminal part of a calcium-binding protein 
(Fh8, GenBank ID: AF213970.1) excreted and secreted by the 
adult worm of Fasciola hepatica.23 The H sequence was recently 
suggested as a fusion partner, and it showed to improve protein 
expression yields in E. coli, though it did not function as solubil-
ity tag.24
The utility of the H tag as a fusion partner for recombinant 
antigen and antibody production is here demonstrated by using 
the CP12 protein, which, as a surface adhesion protein, plays a 
major role in the diagnosis of C. parvum infections in various 
mammals, including humans.25 A higher availability of this anti-
gen and its specific polyclonal antibodies is therefore important 
for cryptosporidiosis prevention and therapy. In addition, the low 
molecular weight of the H fusion partner (1 kDa) makes it a par-
ticularly attractive option for use in antibody production.
Results
Expression and purification of CP12 in E. coli using the H 
fusion partner. The sequence of cp12 gene cloned into pQE-30 
and pQEH vectors (Fig. 1) matches 100% identity with the orig-
inal cp12 sequence except that it lacks the original N-terminal 
peptide signal and transmembrane region.
Results of protein purification were analyzed by SDS-PAGE 
(Fig. 2), and revealed that both CP12 and HCP12 proteins were 
obtained at the predicted 10 kDa and 11 kDa, respectively. After 
being purified, CP12 non fused protein achieved a production 
yield of 0.40 ± 0.050 mg per liter of E. coli culture while HCP12 
fusion protein achieved a production yield of 1.5 ± 0.30 mg per 
liter of E. coli culture.
Production of polyclonal antibodies using the H tag. ELISA 
assays showed similar results for both CP12 and HCP12 ELISA 
coatings (Figs. 3A and B): an increased humoral immune 
response was observed in CP12 and HCP12-injected mice. When 
fused to the H partner, CP12 antigen was able to trigger an earlier 
immune response than the non-fused antigen: the IgG levels for 
HCP12-injected mice started to increase after the 14th day post 
injection, while IgG levels for CP12-injected mice only increased 
after the 28th day post injection (Fig. 3A). Furthermore, HCP12 
mice group achieved higher polyclonal antibody titers than those 
obtained with CP12-injected group.
Humoral response against the H partner. For all sera ana-
lyzed, no significant IgG levels were observed in plates coated 
with Fh8 or HTgOWP antigens. Neither CP12-immunized nor 
HCP12-immunized sera reacted with HTgOWP (Fig. 3C) and 
Fh8 (Fig. 3D) antigens.
Fusion partners, such as SpA,2 GST,19 BB-SpG,18 MBP,17 
and Trx,20 have been used to improve both antigen expression 
and antibody production. However, these fusion partners have 
also been shown to have drawbacks. In some cases, the result-
ing recombinant antigen is not sufficiently soluble or pure.1,19 
In others, the immune response obtained against fusion anti-
gens is often triggered predominantly by the fusion partner 
itself, rather than by the target antigen.1,2,19,21 And in others still, 
the fusion partners have shown inadequate immunopotentiat-
ing properties to elicit the production of sufficient quantities 
of the antibodies of interest. In such cases, during immuni-
sation, it is necessary to co-administer an adjuvant. Despite 
being widely used for routine antibody production in animals, 
Figure 1. amino acid and nucleotide sequences of the hcp12 codifying 
gene.
Figure 2. sDs-paGe analysis of purified cp12 and hcp12 proteins after 
nickel affinity chromatography (5 μg of protein per lane).
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Recognition of native CP12 epitopes. The immunofluo-
rescence results revealed that the control serum did not detect 
the C. parvum oocyst presented at Figure 4C. The fluorescence 
observed in Figure 4C and D highlights the surface of C. parvum 
oocysts, thus confirming the ability of the CP12- and HCP12-
immunized serum to detect the native CP12 epitopes displayed 
on the surface of parasite oocysts.
Discussion
A novel approach to produce CP12 specific polyclonal antibodies 
is presented in this work, in which the H tag plays an important 
role for adjuvant-free immunisation.
Taking into account CP12 diagnostic and prophylactic rel-
evance in the control of C. parvum infections in various organ-
isms, novel strategies to improve this antigen production and its 
specific polyclonal antibodies availability are desired.
Following a production strategy from gene to antibody, the 
study conducted here reveals several advantages of using the H 
partner to produce polyclonal antibodies. The H partner improves 
These assays demonstrated that the H partner did not 
trigger itself a humoral response, since polyclonal antibodies 
anti-HCP12 were not capable to interact with H-containing 
antigens.
CP12 specific polyclonal antibodies. Western blot analyses 
with CP12- and HCP12-immunized sera (collected 7 d after 8th 
IP) revealed the formation of blots at a molecular weight that 
corresponds to dimer and possible oligomer forms (resistant to 
denaturing and reducing conditions) of Fh8CP12 antigen (36 
KDa).The western blot analysis performed with the sera from the 
mice control group did not reveal blot formation, as expected 
(Fig. 4A, lane 3).
An immunoblotting analysis using the Fh8 recombinant anti-
gen was also performed with HCP12-,CP12-immunized sera 
and sera from the mice control group, in the same conditions as 
above, but no blots were observed (Fig. 4B).
Western blot analyses showed that polyclonal antibodies pro-
duced by HCP12-injected mice group did not cross react with 
the H partner existent in the Fh8 protein and specifically recog-
nized the CP12 antigen.
Figure 3. evaluation of IgG production against cp12 and hcp12 antigens during the course of immunisation. eLIsas were performed with sera collect-
ed periodically from cD1 mice experimentally injected with hcp12 (here presented as anti-hcp12), with cp12 (here presented as anti-cp12), and from 
non-injected mice (here presented as NeG). 1st/3rd/5th/7th/8th Ip, Blood collection before 1st/3rd/5th/7th/8th intraperitoneal injections. D56, Blood 
collection at seven days after 8th Ip. Open cross circles and open diamonds, O. D. values statistically different from negative control. closed stars, O. D. 
values statistically different from cp12-injected mice. (A) plates coated with 10 μg.mL−1 of cp12. (B) plates coated with 10 μg.mL−1 of hcp12. (C) plates 
coated with 10 μg.mL−1 of hTgOWp (fusion antigen composed by the h partner and the TgOWp—oocyst wall protein of Toxoplasma gondii). (D) plates 
coated with 10 μg.mL−1 of Fh8 (a calcium binding protein and a solubility fusion tag that contains the h partner sequence in its N-terminal).
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adjuvant stimulations are not desirable as they can be difficult to 
prepare or may cause several side effects, namely, chronic inflam-
mation response at the injection site. In addition, the immune 
responses obtained with large fusion partners are frequently not 
specific for the target antigen, resulting in polyclonal antibodies 
production against both fusion moiety and target antigen. For 
most antibody applications, extra purification steps need to be 
conducted, which makes this a time-consuming and expensive 
methodology.
Taking into account all these aspects, the ability of the H 
partner to effectively improve the specific immunogenicity of 
CP12 protein without adjuvants makes this fusion tag an inno-
vative alternative to the traditional immunisation methods and 
an attractive option to the existent and commonly used fusion 
partners. Furthermore, the H partner has only 1 kDa, which is, 
to our knowledge, the lowest molecular weight partner used for 
protein and antibody production. Moreover, polyclonal antibod-
ies produced by this novel strategy can be used as a diagnostic 
specific antibody production against CP12 antigen, resulting in 
an earlier immune response and in higher polyclonal antibody 
titers when compared with the non-fused CP12 immunisation. 
Moreover, HCP12-immunized sera react only with CP12 antigen 
but not with the H moiety contained in the N-terminal part of 
the Fh8 antigen as well as in the HTgOWP antigen. This CP12 
specific immune response results from immunisation of HCP12 
antigen without using adjuvants, whereby the immunogenicity 
rise may be exclusively due to the fusion of CP12 recombinant 
antigen with the H partner.
CP12 antigen is not very immunogenic and its low molecu-
lar weight can hinder the production of polyclonal antibodies. 
When producing such low molecular weight antigens, fusion 
partners and adjuvants are usually needed to increase the protein 
molecular weight and consequent immune response. However, 
fusion partners like GST,19 Trx,20 BB-SpG,18 MBP,17 and SpA2 or 
SSNAP21 and CTB,26,27 which act themselves as adjuvants, are 
often not capable to elicit a satisfactory immune response, and 
Figure 4. evaluation of polyclonal antibodies specificity against cp12 antigen. (A) western blot analysis of Fh8cp12 antigen. arrows focus the detected 
dimeric form of Fh8cp12 antigen. (B) western blot analysis of Fh8 antigen. In all images, 1, 2 and 3, sera from mice 1, 2, and 3 of each group; anti-
hcp12, polyclonal antibodies produced by hcp12-injected mice; anti-cp12, polyclonal antibodies produced by cp12-injected mice; NeG, Negative 
sera. M, protein marker (Biorad); a, Fh8cp12-loaded antigen stained with amido schwartz reagent. (C) Immunofluorescence assay using negative 
serum (1000-fold total amplification). (D) Immunofluorescence assay using cp12-immunized serum: detection of C. parvum oocysts surface (1000-fold 
total amplification). (E) Immunofluorescence assay using hcp12-immunized serum: detection of C. parvum oocysts surface (1000-fold total amplifica-
tion).
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1 mM of isopropyl-β-D-1-thiogalactopyranoside (IPTG) for 5 h 
at 37 °C. After induction, cells were harvested by centrifugation 
at 4000 g during 15 min at 4 °C, and the resultant pellet was 
lysed with 8 M urea, pH 8.0, overnight at room temperature, 
150 rpm. Cell extracts were centrifuged at 10000 g, 20 min and 
the resulting supernatants and pellets were collected to further 
analyses.
The supernatant fraction was applied onto a Ni-NTA column 
(GE Healthcare, Catalog # 17–5268–02), pre-equilibrated with 
8 M urea, pH 8.0. Ni-NTA purification was conducted accord-
ing to the manufacturer’s instructions, and the protein elution 
was performed by a pH decrease from 8.0 to 4.5.
All CP12 and HCP12 production procedures were repeated in 
three different periods of time to obtain biological independent 
replicates. Recombinant antigens (HCP12 and CP12) adminis-
trated to CD1 mice were dialysed against phosphate saline buf-
fer 1x (PBS), prepared in apyrogenic water (B Braun, Catalog # 
L8502), pH 7.2, and concentrated using Centricon 3 (Millipore, 
Catalog # UFC800308). Pyrogens from concentrated recombi-
nant antigen solutions were removed with Detoxi-Gel Endotoxin 
Removing Gel (Pierce, Catalog # 20339) according to the manu-
facturer’s instructions. Recombinant antigen samples were recov-
ered in pyrogen-free water (Braun, Catalog # L8502) and stored 
at –20 °C until use.
Protein electrophoresis and protein determination. The 
purity of collected fractions from Ni-NTA chromatography was 
analyzed by 17–4% SDS-PAGE gels stained with Coomassie 
brilliant blue dye. 15–4% tris-tricine gels were also used for west-
ern blot analyses, as described below. Protein samples were pre-
pared in a buffer containing sodium dodecyl sulfate (SDS) and 
β-mercaptoethanol, and they were heated prior loading. Protein 
content of each collected fraction and final production yields 
were determined by Bradford assay.
Immunizations. Polyclonal antibodies were produced in CD1 
female mice with 10 to 12 weeks old purchased from Charles 
River SA, Barcelona. The animals were housed and maintained 
with food and drink ad libitum.
For immunisation, groups of three mice were injected intra-
peritoneally (IP) at 2 week intervals with 20 μg of antigen (CP12 
or HCP12) in 200 μl of inocula, without using any adjuvant. 
Purified recombinant antigens were diluted in pyrogen-free phys-
iological serum (Braun, batch # 5144B15) to a concentration of 
0.5 mg mL−1, filtered by 0.2 μm membrane in sterile conditions, 
prior to administration. Control animals harbouring the same 
age and characteristics did not receive either protein or inocula.
Blood collection was performed for five times at 3rd IP, 5th 
IP, 7th IP, 8th IP at the tail vein and mice were sacrificed 1 week 
later. After blood collection, mice sera were separated by centrifu-
gation at 2500 g for 10 min and then stored at -20 °C.
All animal experiments were performed in accordance to 
the European Communities Council Directive of 24 November 
1986 (86/609/EEC).
ELISA. The antibody titer was determined by ELISA. Briefly, 
96-well microtiter plates were coated with HCP12 fusion antigen 
or CP12 antigen (both at 10 μg mL−1) by incubating overnight 
at 4 °C. Bovine serum albumin (BSA) at 3% (w/v) in PBS 1x 
tool for immunodetection of C. parvum infections in humans or 
animals. A small fusion partner like the H tag may not interfere 
negatively with target antigen conformation and, hence, poly-
clonal antibodies raised against antigens fused to the H partner 
are able to recognize native antigen structures.
The low molecular weight of H partner may also clarify the 
reason why this moiety does not trigger an immune response 
against itself when fused to a target antigen.
Materials and Methods
Fusion vector. The H fusion partner containing the restriction 
sites for BamHI and SacI enzymes was introduced into pQE-
30 vector (Qiagen) between the restriction sites for the same 
enzymes (Fig. 1). The resulting fusion vector is a modified pQE-
30 vector with a H tag sequence site, named as pQEH, after the 
N-terminal polyhistidine. The H vector contains a multiple clon-
ing site similar to pQE-30 vector, and codifying gene sequences 
can be cloned immediately after the fusion tag using the specific 
restriction site for SacI enzyme. The H fusion tag has a molecular 
weight of only 1 kDa.
Construction of target expression vectors. The cp12 gene 
used in this work (Fig. 1) corresponds to a truncated form of the 
original cp12 gene: it lacks the original N-terminal peptide sig-
nal and transmembrane region. This truncated gene (cp12 gene) 
was obtained from genomic DNA of C. parvum by a PCR using 
the forward primer: 5'-CATACTGGTA TGAGCTCGAA 
GGAGTAC-3' and the reverse primer: 5'-CATTAAAAGG 
TACCTTTCAT TATCAAG-3'. The forward primer intro-
duced a restriction site for SacI enzyme (bold) between the C. 
parvum genomic DNA sequence (corresponding to an intron) 
and the initial part of cp12 gene (underlined). The reverse 
primer introduced a restriction site for KpnI enzyme (bold) 
between the final part of cp12 gene (underlined) and the C. par-
vum genomic DNA sequence. The PCR product was cloned into 
pGEM T-easy vector (Promega, Catalog # A1360), according to 
manufacturer’s instructions, and used to transform E. coli XL1 
strain. Positive clones were selected and sequenced using pQE 
universal primers.
pGEM plasmid containing the cp12 gene was digested with 
SacI and KpnI restriction enzymes (Promega, Catalog # R6061 
and R6341) and the cp12 gene was then cloned into the same 
restriction sites of pQE-30 (Qiagen, Catalog # 32915) and 
pQEH (Hitag®), using T4 DNA ligase (Promega, Catalog # 
M1801). Following this strategy, E. coli M15 [pREP4] cells 
were transformed with pQE-30 (Qiagen, Catalog # 32915) and 
pQEH (Hitag®) expression vectors containing the 237 bp cp12 
gene. Positive clones were confirmed by DNA sequencing (as 
mentioned above) and the resulting sequence was aligned to cp12 
(GenBank ID: XM625821.1).
LB medium plates supplemented with ampicillin (100 
μg.mL−1) and kanamycin (50 μg.mL−1) were used to select and 
maintain E. coli M15 [pREP4] transformants.
Expression and purification of CP12 proteins in E. coli. 
Cells were grown at 37 °C in LB medium supplemented with 
ampicillin and kanamycin. The E. coli culture was induced with 
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was performed using 4-chloro-1-naphthol in cold methanol, PBS 
1x and hydrogen peroxide.
Immunofluorescence assay (IFA). Immunofluorescence 
assays were conducted to evaluate the potential of polyclonal 
antibodies produced by HCP12- and CP12-injected mice to 
recognize native CP12 epitopes presented on the surface of the 
parasite C. parvum. C. parvum oocysts were isolated from posi-
tive fecal samples of animals by using cesium chloride density 
gradients.28 Isolated oocysts were counted using a Newbauer 
chamber, and added to the slides for testing. Oocysts were air-
dried onto slides, then fixed with acetone and incubated at 37 °C 
in a humid atmosphere with either diluted HCP12-immunized 
sera, CP12-immunized sera or negative control sera. After being 
washed twice with PBS 1x, oocysts were incubated with diluted 
anti-mice IgG conjugated with FITC, according to the manufac-
turer’s instructions. This conjugate was used to reveal the bound 
antibodies, which were then observed using a fluorescence micro-
scope (photos were taken with a 1000-fold total amplification).
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containing 0.3% (v/v) of Tween 20 (PBST) was then used for 
blocking the wells. Diluted HCP12-, CP12-immunized sera or 
negative serum (from the non-injected group) was dispensed into 
each well and plates were incubated at 4 °C overnight. Protein 
A-Horseradish Peroxidase mixed with Protein G- Horseradish 
Peroxidase were used as conjugates, and o- phenylenediamine in 
0.2 M phosphate buffer (pH 5.6) was used for the membrane 
revelation step. The reaction was stopped by adding 3 M HCl 
solution.
The optical density (O.D.) was measured at 492 nm using an 
ELISA reader. ELISA measurements were submitted to a Mann-
Whitney U test with 95% confidence level.
H tag specific humoral response assay. For testing the spe-
cific humoral response against H tag, several ELISAs were per-
formed using two different proteins as coating antigens: Fh8 
and HTgOWP—a Toxoplasma gondii oocyst wall protein, which 
contain the H-tag sequence at their N-terminal, with CP12-, 
HCP12-immunized sera and negative sera. 96-well microtiter 
plates were coated with Fh8 or HTgOWP antigens (both at 10 
μg mL−1), and were subsequently treated following the above-
mentioned ELISA protocol.
Western blot. In this analysis we used Fh8CP12 and Fh8 
antigens to test if there were cross reactions with the H part-
ner, which DNA sequence is part of Fh8 sequence. Tris-Tricine 
gel containing recombinant Fh8CP12 or Fh8 antigens (prepared 
in a buffer with SDS and β-mercaptoethanol and heated prior 
loading) were transferred to nitrocellulose membranes using 
a sandwich system. A strip containing the protein marker and 
part of the Fh8CP12-loaded antigen was cut from the nitrocel-
lulose membrane and stained with Amido Schwartz reagent. The 
rest of the membrane was saturated with a 5% (w/v) PBS-Milk 
solution for 1h at room temperature (RT). Diluted anti-HCP12, 
anti-CP12 or negative group sera were added to different strips 
of the membrane and incubated overnight at 4 °C. Diluted 
Protein G-peroxidase was used as conjugate. Protein detection 
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